albuterol HFA (Armstrong's) + albuterol HFA (Proventil HFA) + HFA placebo
Phase 3Terminated 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma
Trial Timeline
Sep 1, 2007 โ Aug 1, 2008
NCT ID
NCT00635505About albuterol HFA (Armstrong's) + albuterol HFA (Proventil HFA) + HFA placebo
albuterol HFA (Armstrong's) + albuterol HFA (Proventil HFA) + HFA placebo is a phase 3 stage product being developed by Amphastar Pharmaceuticals for Asthma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00635505. Target conditions include Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00635505 | Phase 3 | Terminated |
Competing Products
20 competing products in Asthma
Other Products from Amphastar Pharmaceuticals
E004 (Epinephrine Inhalation Aerosol) HFA-MDI + Placebo-HFAPhase 3
72
albuterol (Armstrong Albuterol HFA) + Albuterol Sulfate (Provenetil-HFA) + Placebo-HFAPhase 3
72
Placebo + Primatene Mist + Epinephrine inhalationPhase 3
72
Armstrong Albuterol Sulfate Inhalation Aerosol + Albuterol Sulfate Inhalation AerosolPhase 3
72
Epinephrine HFA-MDI (E004) + Placebo-HFAPhase 3
72